Ironwood Pharma (IRWD) Misses Q1 EPS by 12c, Sales Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. CRWD
2. REGN
3. ABBV
4. CL
5. LYB
6. TFII
7. NVT
8. SPY
9. AAPL
10. LITE

Go back to Ironwood Pharma (IRWD) Misses Q1 EPS by 12c, Sales Miss

Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update

May 8, 2017 8:00 AM EDT

LINZESS® (linaclotide) U.S. net sales grew to $148 million in 1Q 2017, primarily driven by more than 20% growth in LINZESS volume year-over-year

Three LINZESS doses now available with the introduction of 72 mcg dose

Multiple 2017 pipeline catalysts expected, including IW-3718 Phase IIb data for uncontrolled GERD and DUZALLO approval

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Ironwood Pharmaceuticals, Inc.... More